Бизнес · 17.07.20201 мин чтения
Eli Lilly and Co.; Announcement of the Revocation of the Biologics License for LARTRUVO
Локальный автоматический перевод · Язык оригинального источника
Краткое содержание
The Food and Drug Administration (FDA or Agency) is announcing the revocation of the biologics license application (BLA) for LARTRUVO (olaratumab) injection. Eli Lilly and Co. requested withdrawal (revocation) of the biologics license application and has waived its opportunity for a hearing.